Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR)
- PMID: 30885514
- DOI: 10.1016/j.tracli.2019.02.006
Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR)
Abstract
Sickle cell disease (SCD) is the most prevalent genetic disorder in France. Many other countries are also affected. Transfusion is still a key treatment for patients suffering from this condition. As a result, SCD patients are much more exposed to transfusions and their risks than the general population. The most feared situation is delayed hemolytic transfusion reaction (DHTR). In certain situations, defined as hyperhemolysis, autologous red blood cells (RBCs) are also targeted and destroyed. This can put the patient in a life-threating situation. Further transfusions worsen the hemolysis. As DHTR will mimic a new or resistant vaso-occlusive crisis, it can be easily underdiagnosed. SCD patients are more likely to be alloimmunized than the general population, due to discrepancies between the recipient's and donor's RBCs phenotypes. Furthermore, they are often transfused in an inflammatory state, and they also frequently harbor partial antigens in the RH system. SCD patients are more prone to develop a new alloantibody than the general population. As a result, patients with DHTR often have complex mixtures of allo and autoantibodies; RH antibodies and those considered as irregular natural antibodies are frequent. Nevertheless, about a third of DHTRs are reported in patients with no previous history of immunization. In addition, a third of SCD patients will not develop an antibody after a DHTR. The evanescence of the antibodies is important. In several studies, DHTRs were reported only in patients who were occasionally transfused. Identifying patients at risk of developing a DHTR is key to managing them properly.
Keywords: Antibody screen and identification; Antigènes partiels; Delayed hemolytic transfusion reaction; Dépistage et identification d'anticorps anti-érythrocytaires; Groupe sanguin rare; Partial antigens; Patient drépanocytaire; Rare blood type; Réaction hémolytique retardée post-transfusionnelle; Sickle cell disease patient.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.Pediatrics. 2003 Jun;111(6 Pt 1):e661-5. doi: 10.1542/peds.111.6.e661. Pediatrics. 2003. PMID: 12777582
-
Prevention of delayed hemolytic transfusion reaction.Transfus Clin Biol. 2019 May;26(2):99-101. doi: 10.1016/j.tracli.2019.02.007. Epub 2019 Feb 22. Transfus Clin Biol. 2019. PMID: 30926306
-
Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.Transfusion. 2019 Jun;59(6):1907-1910. doi: 10.1111/trf.15198. Epub 2019 Feb 15. Transfusion. 2019. PMID: 30768787 Review.
-
Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.Transfus Clin Biol. 2019 May;26(2):94-98. doi: 10.1016/j.tracli.2019.02.002. Epub 2019 Feb 22. Transfus Clin Biol. 2019. PMID: 30837199 Review.
-
Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.J Pediatr Hematol Oncol. 2019 Nov;41(8):624-626. doi: 10.1097/MPH.0000000000001307. J Pediatr Hematol Oncol. 2019. PMID: 30179992 Review.
Cited by
-
Investigation of Delayed Transfusion Reactions in Sickle Cell Disease Patients Polytransfused in the Brazilian Amazon.Hematol Rep. 2024 Aug 1;16(3):512-522. doi: 10.3390/hematolrep16030049. Hematol Rep. 2024. PMID: 39189245 Free PMC article.
-
Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Case Report.Int Med Case Rep J. 2020 Jul 28;13:307-311. doi: 10.2147/IMCRJ.S257036. eCollection 2020. Int Med Case Rep J. 2020. PMID: 32801941 Free PMC article.
-
Would a National Antibody Register contribute to improving patient outcomes?Blood Transfus. 2022 Mar;20(2):132-142. doi: 10.2451/2021.0421-20. Epub 2021 Mar 12. Blood Transfus. 2022. PMID: 35244534 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials